Immunogenic cell deathPrognostic signatureTumor immune microenvironmentChemotherapyCurrent literatures suggest a growing body of evidence highlighting the pivotal role of Immunogenic Cell Death (ICD) in multiple tumor types. Nevertheless, the potential and mechanisms of ICD in diffuse large B-cell lymphoma ...
摘要: Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive subtype of non-Hodgkin's lymphomas, with limited treatment options in refractory and relapsed patients. Growing evi... 查看全部>>关键词: CXCR5(+) CD8(+) T cell Diffuse large B-cell lymphoma Interleukin 10 ...
High dose Bortezomib plus second line chemo-therapy in treatment of patients with fractory and relapsed diffuse large B cell lymphoma,West China Hospital of Sichuan University,Observational,Not Applicable
Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Economic models have predicted rituximab plus CHOP (RCHOP) to be a cost-effective alternative to CHOP alone as...
Monoallelic inactivating mutations of CBP or EP300 in DLBCL suggest that reduced functional levels of the enzymes are important for lymphomagenesis [9]. To study the effects of reduced levels of functional protein, the GC-derived diffuse large B-cell lymphoma cell line SUDHL4 was selected, base...
In addition to individual variants, recent studies have evaluated genome-wide genetic correlations between pairs of cancer types4,5,6. One evaluated 13 cancer types and found shared heritability between kidney and testicular cancers, diffuse large B-cell lymphoma (DLBCL) and osteosarcoma, DLBCL and...
S2k-Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021 2022, JDDG - Journal of the German Society of Dermatology Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: An individual patient-level analysis of multiple randomiz...
Having revealed the shared genetic architecture among the genes and diseases, we wondered the pleiotropic effects of the identified coding variants. To comprehensively assess this, we performed PheWAS across a total of 175 clinical outcomes identified by ICD-10 codes38in the UKB. For genes identified...
Having revealed the shared genetic architecture among the genes and diseases, we wondered the pleiotropic effects of the identified coding variants. To comprehensively assess this, we performed PheWAS across a total of 175 clinical outcomes identified by ICD-10 codes38in the UKB. For genes identified...
Non-Hodgkin lymphoma 1091 0.99 (0.94–1.05) 1 1.03 (0.86–1.24) 1.00 (0.82–1.21) 1.00 (0.82–1.23) 0.96 Diffuse large B-cell lymphoma 210 1.04 (0.92–1.17) 1 1.40 (0.88–2.23) 1.48 (0.92–2.38) 1.63 (1.00–2.66) c 0.06 Follicular lymphoma 154 0.89 (0.75–1.05) 1 0.78 (0.48–1.26...